



Optimizing Antimicrobial Use: Antimicrobial Stewardship and Surveillance

Guest Editor:

Dr. Jesus Ruiz-Ramos

Pharmacy Department, Hospital
Santa Creu i Sant Pau. C/San
Quintín 89, 08041 Barcelona,
Spain

Deadline for manuscript
submissions:

15 December 2024

Message from the Guest Editor

Dear Colleagues,

During the last few decades, the implementation of antimicrobial stewardship programs has become more widespread in health centers. The objectives of these programs are to reduce the use of antimicrobials, reduce the duration of broad-spectrum antibiotic treatments, and to optimize individualized antibiotic treatment for the patient with the best efficacy and safety results, to slow down the advance of MDR pathogens. Even though there is ample evidence that the application of these multidisciplinary programs reduces the consumption of antimicrobials globally, the heterogeneity of the practices used and the unequal impact on the selection and infection by MDR strains make it essential to continue studying which interventions have a greater impact within these programs. This Special Issue seeks manuscript submissions that further our understanding of antimicrobial stewardship programs' impact on bacterial resistance. Submissions on the impact of antimicrobial stewardship over bacterial resistance are especially encouraged.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi